Talphera (TLPH) Net Shares Issued and Repurchased (2010 - 2026)
Talphera (TLPH) posted Net Shares Issued and Repurchased of $1.5 million for Q1 2026, up 57.71% on a QoQ basis from $919781.0 in Q4 2025, and up 18032.5% year-over-year from N/an in Q1 2025.
Analysis
Talphera (TLPH) Net Shares Issued and Repurchased (2010 - 2026) Analysis & Trends
Talphera has reported Net Shares Issued and Repurchased for 17 years, with the latest figure at $1.5 million in Q1 2026.
- On a quarterly basis, Net Shares Issued and Repurchased rose 18032.5% year-over-year to $1.5 million in Q1 2026; TTM through Mar 2026 was $1.5 million, a 18032.5% increase from a year earlier, with the FY2025 full-year figure at $919781.0, down 12.7% from the prior year.
- Net Shares Issued and Repurchased was $1.5 million for Q1 2026 at Talphera, up from $919781.0 in the prior quarter.
- The five-year high for Net Shares Issued and Repurchased was $2.1 million in Q1 2022, with the low at $8000.0 in Q1 2025.
- Average Net Shares Issued and Repurchased over 5 years is $779606.9, with a median of $790348.0 recorded in 2024.
- The sharpest annual moves came in 2025 and 2026: Net Shares Issued and Repurchased tumbled 98.99% in 2025, then jumped 18032.5% in 2026.
- Over 5 years, Net Shares Issued and Repurchased stood at $117022.0 in 2022, then jumped by 146.9% to $288929.0 in 2023, then surged by 264.66% to $1.1 million in 2024, then declined by 12.7% to $919781.0 in 2025, then surged by 57.71% to $1.5 million in 2026.
- The last three Net Shares Issued and Repurchased figures came in at $1.5 million (Q1 2026), $919781.0 (Q4 2025), and $8000.0 (Q1 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Shares Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Talphera | 92.90 Mn | 92.90 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 1.45 Mn |
| Dec 31, 2025 | 919,781.00 |
| Mar 31, 2025 | 8,000.00 |
| Dec 31, 2024 | 1.05 Mn |
| Mar 31, 2024 | 790,348.00 |
| Dec 31, 2023 | 288,929.00 |
| Mar 31, 2023 | 264,520.00 |
| Dec 31, 2022 | 117,022.00 |
| Mar 31, 2022 | 2.12 Mn |
| Dec 31, 2021 | 2.67 Mn |
| Dec 31, 2020 | 1.82 Mn |
| Dec 31, 2019 | 2.06 Mn |
| Dec 31, 2018 | 3.55 Mn |
| Dec 31, 2017 | 3.01 Mn |
| Dec 31, 2016 | 1.89 Mn |
| Dec 31, 2015 | 997,099.00 |
| Dec 31, 2014 | 2.51 Mn |
| Dec 31, 2013 | 1.96 Mn |
| Dec 31, 2012 | 1.21 Mn |
| Dec 31, 2011 | 514,958.00 |